Indication and Usage of Ibrutinib
Ibrutinib comes under the brand name Imbruvica. It is an anticancer medicine that belongs to a class of drugs called protein kinase inhibitors. The ibrutinib medication is available as immediate-release oral capsules and immediate-release oral tablets. Ibrutinib capsules for oral administration are available in the following dosage strengths: 70 mg and 140 mg. Although, ibrutinib tablets for oral administration are available in the following dosage strengths: 140 mg, 280 mg, 420 mg, and 560 mg. Ibrutinib is used for the treatment of the following blood cancers in adults: Mantle Cell Lymphoma: Ibrutinib is prescribed for the treatment of adult patients with MCL (mantle cell lymphoma) who have received at least 1-prior therapy. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Ibrutinib is prescribed for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Chronic Lymphocytic Leukemia/Sm...